

Cancer Core Europe (CCE) Virtual Keynote Session on Translational Cancer Research, October 13th, 2020

Program

1:45 pm Check-in (time zone: CEST)

2:00 pm **Welcome**

2:05 pm **Transforming Cancer Care by Innovation: The Cancer Core Europe Vision**




Emile E. Voest

Medical Director of the Netherlands Cancer Institute, Chair of CCE,
The Netherlands

2:35 pm Discussion

2:50 pm **Computational Analysis of Cancer Genomes**



Núria López-Bigas

ICREA Research Professor at the Institute for Research in Biomedicine
(IRB Barcelona), Group Leader at Barcelona Biomedical Genomics Lab, Spain

3:20 pm Discussion

3:30 pm Short break

3:45 pm **Drug Development – The Revolution of the Last 15 Years**



Jean-Charles Soria

General Director of Gustave Roussy, Medical Oncologist and Professor of
Medicine at Paris-Saclay University, CCE Board of Directors, France

4:15 pm Discussion

4:30 pm **Malignant Progression and Metastasis**



Robert A. Weinberg

Founding Member of the Whitehead Institute for Biomedical Research and
Professor of Biology at the Massachusetts Institute of Technology, USA

5:00 pm Discussion

5:15 pm **Closing Remarks**

Moderators

Stefan Fröhling, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center
(DKFZ), CCE Board of Directors, Germany

Ingemar Ernberg, Karolinska Institutet, CCE Board of Directors, Sweden

María Abad, Vall d'Hebron Institute of Oncology, Spain

Register now: www.cancersummerschool.eu

Deadline: October 6th, 2020

Contact: summerschool@nct-heidelberg.de

HOSTED BY



ORGANIZED BY



Cancer Core Europe (CCE) Virtual Keynote Session on Translational Cancer Research, October 13th, 2020

Speakers



Emile E. Voest

Emile Voest is Professor of Medical Oncology and serves as Medical Director on the executive board of the Netherlands Cancer Institute in Amsterdam. He is the current Chair of the Board of Directors of Cancer Core Europe. He also serves on the supervisory board of the Hartwig Medical Foundation (national sequencing center), the ESMO Council, and is senior scientist at the Onco Institute. His research efforts focus on improving systemic treatment for patients with cancer. This includes the clinical development of targeted agents, discovery and validation of biomarkers with emphasis on genetics and tumor organoids, and identification of new targets of treatment to overcome chemoresistance.



Núria López-Bigas

Núria López-Bigas is an ICREA Research Professor at the Institute for Research in Biomedicine and Associate Professor at the University Pompeu Fabra. She was elected member of the European Molecular Biology Organization (EMBO) in 2016. She obtained a grant from the European Research Council Consolidator Grant (ERC-consolidator) in 2015. Her work has been recognized with awards such as the prestigious Banc de Sabadell Award for Research in Biomedicine, the Catalan National Award for Young Research Talent, and the Career Development Award from the Human Frontiers Science Program Organization. Her research focuses on the identification of cancer driver mutations, genes and pathways across tumor types, and in understanding the mutational processes leading to the accumulation of mutations in cancer cells.



Jean-Charles Soria

Jean-Charles Soria is Professor of Medicine and Medical Oncology at South-Paris University since 2006. Professor Soria was Chairman of the Drug Development Department at Gustave Roussy Cancer Center (2013-2017) and was a member of the lung cancer unit with a focus on targeted therapies (2001-2017). He was the Director of the Gustave Roussy SIRIC research program from 2013-2017. From 2017 to 2019, Professor Soria was Senior Vice President at AstraZeneca in charge of early oncology research and development with specific accountability for immunotherapy, antibody-drug conjugates and cell therapy. Jean-Charles Soria was appointed the General Director of Gustave Roussy Cancer Center in January 2020. He is a highly-cited clinician scientist.



Robert A. Weinberg

Robert A. Weinberg was born in Pittsburgh in 1942 to a family of refugees from Germany, where he received his primary and secondary school education. He received his B.S. and Ph.D. degrees in biology from the Massachusetts Institute of Technology (MIT) under the mentorship of Sheldon Penman. He taught during 1965-66 in the Department of Biology of Stillman College, Tuscaloosa, Alabama. He undertook postdoctoral research at the Weizmann Institute, Rehovot, Israel in the laboratory of Ernest Winocour and at the Salk Institute, LaJolla, California with Renato Dulbecco, and then returned to MIT in 1972. In 1982, he was appointed Professor of Biology at MIT. He is a founding member of the Whitehead Institute for Biomedical Research, the Daniel K. Ludwig Professor for Cancer Research, and an American Cancer Society Research Professor at the Massachusetts Institute of Technology. His research has been focused on the genetic basis of human cancer. He and his colleagues isolated the first human-cancer-causing gene - the Ras oncogene - and the first known tumor-suppressor gene - Rb, the retinoblastoma gene. Over the past decade his research has focused on the molecular and cellular mechanisms of malignant progression, including cancer cell invasion and metastasis.

HOSTED BY



ORGANIZED BY



NATIONAL CENTER
FOR TUMOR DISEASES
HEIDELBERG

supported by
German Cancer Research Center (DKFZ)
Heidelberg University Medical Center
Hospital for Therapeutic Clinicians
German Cancer Aid